WO2020185056A3 - 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제 - Google Patents

타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제 Download PDF

Info

Publication number
WO2020185056A3
WO2020185056A3 PCT/KR2020/095016 KR2020095016W WO2020185056A3 WO 2020185056 A3 WO2020185056 A3 WO 2020185056A3 KR 2020095016 W KR2020095016 W KR 2020095016W WO 2020185056 A3 WO2020185056 A3 WO 2020185056A3
Authority
WO
WIPO (PCT)
Prior art keywords
immune cell
same
culture obtained
cells
therapeutic agent
Prior art date
Application number
PCT/KR2020/095016
Other languages
English (en)
French (fr)
Other versions
WO2020185056A2 (ko
Inventor
신지섭
신우섭
장민지
신동혁
Original Assignee
신지섭
신우섭
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신지섭, 신우섭 filed Critical 신지섭
Priority to CN202080033852.4A priority Critical patent/CN113795573A/zh
Priority to EP20769957.0A priority patent/EP3967753A4/en
Priority to US17/437,140 priority patent/US20220168348A1/en
Priority to JP2021553758A priority patent/JP2022524146A/ja
Publication of WO2020185056A2 publication Critical patent/WO2020185056A2/ko
Publication of WO2020185056A3 publication Critical patent/WO2020185056A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0643—Osteoclasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/983—Blood, e.g. plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 면역요법에 적용되는 자연살해세포(Natural Killer cell; NK 세포) 배양방법에 관한 것으로, 보다 구체적으로는 면역세포치료제가 투여될 환자가 아니라 건강한 공여자의 혈액에서 유래된 림프구를 배양하여 악성종양 치료에 효과가 뛰어난 NK세포를 효율적으로 증폭 및 활성화시키는 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제에 대한 것이다.
PCT/KR2020/095016 2019-03-08 2020-03-05 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제 WO2020185056A2 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202080033852.4A CN113795573A (zh) 2019-03-08 2020-03-05 培养同种异体免疫细胞的方法、用该方法获得的免疫细胞培养物和包含其的免疫细胞治疗剂
EP20769957.0A EP3967753A4 (en) 2019-03-08 2020-03-05 PROCESS FOR CULTIVATION OF ALLOGOUS IMMUNITY CELLS, IMMUNITY CELL CULTURE OBTAINED THEREBY AND IMMUNITY CELL THERAPEUTIC THEREFORE
US17/437,140 US20220168348A1 (en) 2019-03-08 2020-03-05 Method for culturing allogeneic immune cell, immune cell culture obtained thereby, and immune cell therapeutic agent comprising same
JP2021553758A JP2022524146A (ja) 2019-03-08 2020-03-05 他家免疫細胞培養方法、その方法により得られた免疫細胞培養液、及びこれを含む免疫細胞治療剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0027152 2019-03-08
KR1020190027152A KR102234394B1 (ko) 2019-03-08 2019-03-08 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제

Publications (2)

Publication Number Publication Date
WO2020185056A2 WO2020185056A2 (ko) 2020-09-17
WO2020185056A3 true WO2020185056A3 (ko) 2020-11-05

Family

ID=72426421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/095016 WO2020185056A2 (ko) 2019-03-08 2020-03-05 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제

Country Status (6)

Country Link
US (1) US20220168348A1 (ko)
EP (1) EP3967753A4 (ko)
JP (1) JP2022524146A (ko)
KR (1) KR102234394B1 (ko)
CN (1) CN113795573A (ko)
WO (1) WO2020185056A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
CN116370619B (zh) * 2022-04-02 2024-04-12 北京达尔文细胞生物科技有限公司 一种安全有效的同种异体免疫细胞组合物及其制备方法和其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090127973A (ko) * 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양 방법
KR20130047167A (ko) * 2011-10-31 2013-05-08 이동욱 면역세포 증식 배양액이 함유된 화장료 조성물 제조방법
KR20140043340A (ko) * 2011-04-13 2014-04-09 이뮤니쿰 에이비 T 세포의 프라이밍을 위한 방법
WO2018044809A1 (en) * 2016-08-29 2018-03-08 Hackensack University Medical Center Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans
KR20180057359A (ko) * 2016-11-22 2018-05-30 신동혁 면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029394A1 (en) * 1995-03-17 1996-09-26 The Regents Of The University Of California Method for treating tumors
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
KR20120093978A (ko) * 2009-10-27 2012-08-23 이뮤니쿰 에이비 항원 특이적 ｔ 세포의 증식 방법
JP5572863B2 (ja) * 2011-06-24 2014-08-20 国立大学法人九州大学 Ｎｋ細胞の増幅方法
US20160046715A1 (en) * 2013-05-17 2016-02-18 Abwiz Bio, Inc. T regulatory cells and uses thereof
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
KR101683614B1 (ko) * 2016-02-15 2016-12-07 신동혁 Nk세포배양용 배지첨가키트 및 상기 키트를 이용한 nk세포배양방법
JP2019031470A (ja) * 2017-08-09 2019-02-28 株式会社再生医学研究所 Ｎｋ細胞培養上清を含む抗腫瘍組成物およびその製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090127973A (ko) * 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양 방법
KR20140043340A (ko) * 2011-04-13 2014-04-09 이뮤니쿰 에이비 T 세포의 프라이밍을 위한 방법
KR20130047167A (ko) * 2011-10-31 2013-05-08 이동욱 면역세포 증식 배양액이 함유된 화장료 조성물 제조방법
WO2018044809A1 (en) * 2016-08-29 2018-03-08 Hackensack University Medical Center Compositions and methods for reprogramming adult cells through the stemness of a platelet rich fraction of blood containing platelet-like cells in humans
KR20180057359A (ko) * 2016-11-22 2018-05-30 신동혁 면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물

Also Published As

Publication number Publication date
WO2020185056A2 (ko) 2020-09-17
JP2022524146A (ja) 2022-04-27
EP3967753A2 (en) 2022-03-16
KR102234394B1 (ko) 2021-03-31
EP3967753A4 (en) 2022-12-21
US20220168348A1 (en) 2022-06-02
CN113795573A (zh) 2021-12-14
KR20200107666A (ko) 2020-09-16

Similar Documents

Publication Publication Date Title
Oyer et al. PD-L1 blockade enhances anti-tumor efficacy of NK cells
CN109294985B (zh) 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法
Hsu et al. Prostaglandin E2 potentiates mesenchymal stem cell–induced IL-10+ IFN-γ+ CD4+ regulatory T cells to control transplant arteriosclerosis
Jewett et al. NK cells shape pancreatic and oral tumor microenvironments; role in inhibition of tumor growth and metastasis
Miller et al. Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy
KR101851270B1 (ko) 자연 살해세포의 대량증식 방법 및 배양용 조성물
CA2796379A1 (en) Method for proliferation of antigen-specific t cells
CN103756963A (zh) 一种体外扩增nk细胞的方法
CN108676775B (zh) 一种体外扩增脐血nk的方法
JP2019520061A5 (ko)
CN103648524A (zh) 使用树突细胞和由高静水压力杀死的肿瘤细胞对癌症进行主动细胞免疫治疗的手段和方法
WO2020185056A3 (ko) 타가면역세포배양방법, 그 방법으로 얻어진 면역세포배양액 및 이를 포함하는 면역세포치료제
WO2020000035A8 (en) Modified t cells and uses thereof
WO2019157158A3 (en) Methods for allogenic hematopoietic stem cell transplantation
CN106148282A (zh) 一种自然杀伤细胞的培养方法
IL257929B1 (en) Methods for the treatment of multiple myeloma and plasma cell leukemia using T-cell therapy
KR101968184B1 (ko) 저산소 조건을 이용한 면역세포의 증식 배양 방법
CN105219713A (zh) 用于肿瘤过继性免疫的高增殖力、高杀伤力nk细胞
CN105505871A (zh) 一种有效扩增cik且提高其特异性杀瘤能力的方法
CN105462926A (zh) 一种免疫细胞瘤苗的制备方法及其应用
CN103372029A (zh) 肿瘤治疗用nk细胞新技术
TW202206591A (zh) 體外增殖自然殺手細胞及自然殺手t細胞之方法
CN106822861A (zh) 抗原肽gpc3‑1和gpc3‑3在制备治疗肝癌药物中的应用
Har-Noy et al. Completely mismatched allogeneic CD3/CD28 cross-linked Th1 memory cells elicit anti-leukemia effects in unconditioned hosts without GVHD toxicity
WO2021101273A3 (ko) 조절 t 세포 배양용 조성물 및 이의 용도

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20769957

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2021553758

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020769957

Country of ref document: EP

Effective date: 20211008